Skip to main content

Table 2 Engraftment and GVHD

From: Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

 

No-ATG

ATG

p value

Total number of patients

421

145

 

Engraftment, n (%)

411 (98.6%)

145 (100%)

0.15

 No engraftment, n (%)

6 (1.4%)

0 (0%)

 Missing, n

5

0

Median time ANC > 0.5 G/L (days, range)

15 (5–45)

14 (5–28)

0.001

Acute GVHD,

 Grade 0–I, n (%)

315 (78.2%)

116 (84.7%)

0.10

 Grade II–IV, n (%)

88 (21.8%)

21 (15.3%)

 Grade III–IV, n (%)

31 (7.7%)

6 (4.4%)

0.19

 Missing, n

5

3

Chronic GVHDa

 All grades

52% (46–57.7)

30.8% (22.3–39.8)

0.00026

 Extensive

26.3% (21.2–31.6)

7.6% (3.5–13.7)

4.7 × 10−5

 Limited, n

71

26

 

 Extensive; n

77

8

 Missing, n

117

28

  1. ATG anti-thymocyte globulin, GVHD graft-versus-host disease
  2. aTwo-year cumulative incidence